EP Patent

EP0922042A1 — Novel piperazine containing compounds

Assigned to SmithKline Beecham Ltd · Expires 1999-06-16 · 27y expired

What this patent protects

Novel 3-Carboxyindole piperazine amide containing compounds, and compositions for use in therapy as anti-inflammatory agents, and inhibitors of cytokine p38/MAP kinase mediated diseases.

USPTO Abstract

Novel 3-Carboxyindole piperazine amide containing compounds, and compositions for use in therapy as anti-inflammatory agents, and inhibitors of cytokine p38/MAP kinase mediated diseases.

Drugs covered by this patent

Patent Metadata

Patent number
EP0922042A1
Jurisdiction
EP
Classification
—
Expires
1999-06-16
Drug substance claim
No
Drug product claim
No
Assignee
SmithKline Beecham Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.